GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Total Payout Yield %

CGON (CG Oncology) Total Payout Yield % : -36.92 (As of Apr. 29, 2025)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

CG Oncology's current Total Payout Yield % is -36.92%.


CG Oncology Total Payout Yield % Historical Data

The historical data trend for CG Oncology's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Total Payout Yield % Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Total Payout Yield %
- - - -28.82

CG Oncology Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only - -55.57 - - -

Competitive Comparison of CG Oncology's Total Payout Yield %

For the Biotechnology subindustry, CG Oncology's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CG Oncology's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where CG Oncology's Total Payout Yield % falls into.


;
;

CG Oncology Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

CG Oncology's Total Payout Yield % for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 629.469 + 0) / 2184.1254
=-28.82%

CG Oncology's annualized Total Payout Yield % for the quarter that ended in Dec. 2024 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 0 + 0) * 4 / 2184.1254
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CG Oncology Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


CG Oncology Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of CG Oncology's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


CG Oncology Business Description

Traded in Other Exchanges
N/A
Address
400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.